Abvc Biopharma Stock Buy Hold or Sell Recommendation
| ABVC Stock | USD 0.52 0.02 3.70% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding ABVC Biopharma is 'Strong Sell'. Macroaxis provides ABVC Biopharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ABVC positions.
Check out ABVC Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide. In addition, we conduct extensive research on individual companies such as ABVC and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards ABVC Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
ABVC |
Execute ABVC Biopharma Buy or Sell Advice
The ABVC recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ABVC Biopharma. Macroaxis does not own or have any residual interests in ABVC Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ABVC Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Out of control | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
ABVC Biopharma Trading Alerts and Improvement Suggestions
| ABVC Biopharma generated a negative expected return over the last 90 days | |
| ABVC Biopharma has some characteristics of a very speculative penny stock | |
| ABVC Biopharma has high historical volatility and very poor performance | |
| ABVC Biopharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 152.43 K. Net Loss for the year was (10.52 M) with loss before overhead, payroll, taxes, and interest of (32.89 K). | |
| ABVC Biopharma currently holds about 2.99 M in cash with (4.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 23.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying 150,000 in Licensing Fees |
ABVC Biopharma Returns Distribution Density
The distribution of ABVC Biopharma's historical returns is an attempt to chart the uncertainty of ABVC Biopharma's future price movements. The chart of the probability distribution of ABVC Biopharma daily returns describes the distribution of returns around its average expected value. We use ABVC Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ABVC Biopharma returns is essential to provide solid investment advice for ABVC Biopharma.
| Mean Return | 0.02 | Value At Risk | -8.62 | Potential Upside | 8.47 | Standard Deviation | 5.75 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ABVC Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ABVC Stock Institutional Investors
| Shares | Wells Fargo & Co | 2024-06-30 | 0.0 | Chase Investment Counsel Corp | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 71.6 K | Vanguard Group Inc | 2024-09-30 | 46.9 K | Honkamp Krueger Financial Services Inc | 2024-09-30 | 39 K | Xtx Topco Ltd | 2024-09-30 | 23.4 K | Northern Trust Corp | 2024-09-30 | 19.1 K | State Street Corp | 2024-09-30 | 12.9 K | Two Sigma Securities, Llc | 2024-09-30 | 12.4 K | Tower Research Capital Llc | 2024-09-30 | 2.6 K |
ABVC Biopharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Free Cash Flow | (4.6M) | (7.6M) | (7.5M) | (4.3M) | (3.8M) | (3.6M) | |
| Other Non Cash Items | 2.2M | (91.1K) | 353.0K | 3.5M | 4.1M | 4.3M | |
| Net Income | (10.6M) | (12.0M) | (16.3M) | (10.5M) | (9.5M) | (9.0M) | |
| End Period Cash Flow | 5.0M | 6.6M | 1.4M | 716.8K | 824.3K | 875.2K | |
| Change To Inventory | (88.2K) | (25.8K) | 26.0K | 68.5K | 78.8K | 82.7K | |
| Change In Cash | 4.8M | 1.6M | (5.2M) | (674.9K) | (607.5K) | (577.1K) | |
| Depreciation | 37.1K | 12.0K | 23.8K | 28.5K | 25.7K | 24.1K | |
| Net Borrowings | 896.9K | 2.0M | 2.0M | (273.5K) | (314.5K) | (298.8K) | |
| Change To Netincome | 2.6M | (145.5K) | 5.3M | 6.8M | 7.9M | 8.3M | |
| Investments | 147.8K | (806.0K) | (1.7M) | (360.2K) | (324.2K) | (340.4K) |
ABVC Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ABVC Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ABVC Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ABVC stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 0.27 | |
σ | Overall volatility | 4.71 | |
Ir | Information ratio | -0.01 |
ABVC Biopharma Volatility Alert
ABVC Biopharma exhibits above-average semi-deviation for your current time horizon. ABVC Biopharma is a potential penny stock. Although ABVC Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in ABVC Biopharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on ABVC instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.ABVC Biopharma Fundamentals Vs Peers
Comparing ABVC Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ABVC Biopharma's direct or indirect competition across all of the common fundamentals between ABVC Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as ABVC Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ABVC Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing ABVC Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ABVC Biopharma to competition |
| Fundamentals | ABVC Biopharma | Peer Average |
| Return On Equity | -3.2 | -0.31 |
| Return On Asset | -0.45 | -0.14 |
| Operating Margin | (8.34) % | (5.51) % |
| Current Valuation | 14.46 M | 16.62 B |
| Shares Outstanding | 23.69 M | 571.82 M |
| Shares Owned By Insiders | 22.92 % | 10.09 % |
| Shares Owned By Institutions | 3.01 % | 39.21 % |
| Number Of Shares Shorted | 293.37 K | 4.71 M |
| Price To Book | 1.48 X | 9.51 X |
| Price To Sales | 90.33 X | 11.42 X |
| Revenue | 152.43 K | 9.43 B |
| Gross Profit | (32.89 K) | 27.38 B |
| EBITDA | (8.13 M) | 3.9 B |
| Net Income | (10.52 M) | 570.98 M |
| Cash And Equivalents | 2.99 M | 2.7 B |
| Cash Per Share | 0.09 X | 5.01 X |
| Total Debt | 2.28 M | 5.32 B |
| Debt To Equity | 0.34 % | 48.70 % |
| Current Ratio | 2.68 X | 2.16 X |
| Book Value Per Share | 1.06 X | 1.93 K |
| Cash Flow From Operations | (4.24 M) | 971.22 M |
| Short Ratio | 0.70 X | 4.00 X |
| Earnings Per Share | (0.81) X | 3.12 X |
| Target Price | 2.02 | |
| Number Of Employees | 16 | 18.84 K |
| Beta | 0.82 | -0.15 |
| Market Capitalization | 12.32 M | 19.03 B |
| Total Asset | 14.49 M | 29.47 B |
| Retained Earnings | (65.42 M) | 9.33 B |
| Working Capital | (4.28 M) | 1.48 B |
| Net Asset | 14.49 M |
Note: Acquisition by Smith J.b. of tradable shares of ABVC Biopharma at 0.75 subject to Rule 16b-3 [view details]
ABVC Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ABVC . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About ABVC Biopharma Buy or Sell Advice
When is the right time to buy or sell ABVC Biopharma? Buying financial instruments such as ABVC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ABVC Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ABVC Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 18.175 | Return On Assets | Return On Equity |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.